Profiling complete regression after pre-operative therapy in gastric cancer patients using clinical and pathological data

Article Oncology

Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer

Ina Valeria Zurlo et al.

Summary: The study found that pre-treatment NLR, TILs, and PD-L1 expression are correlated with the response to neoadjuvant chemotherapy and prognosis in LAGC patients, suggesting their significance in selecting patients for chemotherapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study

Ping'an Ding et al.

Summary: This study aims to evaluate the predictive value of pre-treatment SII-PNI score on the sensitivity of sintilimab immunotherapy combined with XELOX chemotherapy in patients with locally advanced gastric cancer. The results showed that SII-PNI score was an independent prognostic factor for predicting progression-free survival.

BMC GASTROENTEROLOGY (2022)

Add to Collection

Article Oncology

Quality Over Volume: Modeling Centralization of Gastric Cancer Resections in Italy

Laura Lorenzon et al.

Summary: This study analyzed GC surgical volumes and 30-day postoperative mortality in Italy and modeled centralization of GC resections based on district case volumes. The results showed a correlation between hospital volume and postoperative mortality, and most Italian districts can achieve a high-volume threshold. However, discrepancies in mortality rates are alarming.

JOURNAL OF GASTRIC CANCER (2022)

Add to Collection

Article Oncology

Evaluation and Comparison of Predictive Value of Tumor Regression Grades According to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma

Yilin Tong et al.

Summary: The study compared the predictive ability of Mandard and Becker TRG in patients with locally advanced gastric cancer, and found no significant difference between the two systems in terms of survival prediction.

CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Surgery

Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes

Christof Kaltenmeier et al.

Summary: In gastric cancer patients receiving neoadjuvant therapy, the rate of pathologic complete response (pCR) is 2.2% and pCR is a significant predictor of survival. Further research is needed to investigate the role of radiation in the neoadjuvant setting and the impact of pCR on survival.

AMERICAN SURGEON (2021)

Add to Collection

Article Oncology

Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies

Masato Hayashi et al.

Summary: This meta-analysis showed that better tumor regression grade (TRG) was associated with improved overall survival (OS) in gastric adenocarcinoma patients treated with neoadjuvant chemotherapy. However, due to variations in histology, configuration, and location of gastric cancer, a more subdivided analysis is recommended for more solid evidence.

EJSO (2021)

Add to Collection

Article Oncology

Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a single-center experience

Pietro Maria Lombardi et al.

Summary: This study found that in patients with advanced gastric cancer undergoing perioperative chemotherapy and radical surgery, tumor regression grade (TRG), lymph node ratio (LNR), and tumor size are independent prognostic factors for disease-free survival (DFS) and disease-specific survival (DSS).

JOURNAL OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Nutrition & Dietetics

Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study

Emanuele Rinninella et al.

Summary: The study found that a high proportion of gastric cancer patients receiving FLOT therapy had muscle wasting, and preoperative FLOT treatment further reduced patients' muscle mass, body mass index, and visceral adipose index. However, these changes were not significantly associated with short-term treatment outcomes.

NUTRIENTS (2021)

Add to Collection

Review Oncology

A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead

Charlotte I. Stroes et al.

Summary: Adding HER2 inhibition for curative treatment of gastroesophageal adenocarcinoma (GEA) may provide improved outcomes, especially with dual HER2 inhibition showing promising pathological complete response rates and disease-free survival. Further investigation in clinical trials is necessary given current research indicating potential benefits of dual targeting.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Article Oncology

Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy

Ziyu Li et al.

Summary: This study with a large sample size found that deficient DNA mismatch repair (dMMR) status was not significantly associated with overall survival (OS) and disease-free survival (DFS) in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant and adjuvant platinum and fluorouracil-based chemotherapy.

JOURNAL OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study

Alessandra Raimondi et al.

Summary: MSI-H status in GC/GEJC patients is prognostic and predictive, showing high sensitivity to immunotherapy and potential for achieving high rates of complete response with pre-operative treatment. The ongoing INFINITY study aims to investigate the role of immunotherapy in neoadjuvant or definitive treatment for MSI-H resectable GC/GEJC patients, potentially avoiding surgery in case of complete response.

CANCERS (2021)

Add to Collection

Article Oncology